Endocyte, Inc.
(NASDAQ : ECYT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.13%53.920.9%$1395.93m
JNJJohnson & Johnson 0.85%180.990.7%$1263.76m
BMYBristol-Myers Squibb Co. -1.86%76.151.0%$1200.63m
MRKMerck & Co., Inc. 0.77%93.020.7%$1171.65m
ABBVAbbVie, Inc. -0.36%150.031.9%$1112.27m
LLYEli Lilly & Co. 3.15%323.341.1%$1017.85m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.15%143.400.0%$499.78m
AZNAstraZeneca Plc 1.05%67.401.0%$486.39m
NVSNovartis AG 0.22%91.460.2%$258.15m
GSKGlaxoSmithKline Plc -0.83%44.050.2%$255.09m
VERUVeru, Inc. 1.50%12.830.0%$252.54m
SIGASIGA Technologies, Inc. 41.91%13.680.0%$209.92m
HZNPHorizon Therapeutics Plc 4.69%94.845.4%$209.26m
SGENSeagen Inc. 2.12%141.395.7%$188.92m
NVONovo Nordisk A/S 1.07%107.740.1%$184.03m

Company Profile

Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.